CytoMed Therapeutics
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 34
- Market Cap
- $18.3M
- Introduction
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee K...
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial
CytoMed Therapeutics secures full approval for Phase I ANGELICA Trial, using allogeneic gamma delta T cells to treat blood and solid tumors, co-supported by Singapore's Ministry of Health. The trial aims to improve CAR-T cell quality, reduce costs, and increase patient access. CytoMed also acquires a Malaysian cord blood bank, enhancing its cell therapy strategy.
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor
A form includes dropdowns for selecting a state, zip code, and country, with California preselected and the United States as the default country.
© Copyright 2024. All Rights Reserved by MedPath